“Arbitrary quarantines and travel restrictions may be politically popular, but they won’t curb the outbreak or protect Americans...These measures are also unlawful.” Why the US must urgently pivot from me, @jennifernuzzo.bsky.social & @gostin.bsky.social in @thehill.com thehill.com/opinion/heal...

So much we need to learn about tick-related infections, so this effort by HHS is welcome. But I worry deeply about the company they keep in their announcement. More here: #IDSky #Medsky voices.nejm.org/doi/full/10....

Use this link if you want quick access to #Ebola content across the Lancet journals www.thelancet.com/ebola

Early case series on toci for hantavirus pulmonary syndrome by Fernando Tortosa and colleagues. I'm pleased to publish this work by researchers from Argentina, where Andes virus is endemic and resources are limited (eg ECMO not widely available).

Look at that -- an mpox mRNA vaccine!! Tapping the sign, could we please have funding and appropriate regulation for mRNA vaccines back?

I have the impression that there are more trials with late registration, unexplained changes in primary outcome, analysis population or similar. Subjective and maybe I'm sensitized. Most look to me like some level of sloppiness, not deception. Is this a sign of the strain researchers are under?

Apologies for anyone who follows me for anything else than Ebola. I did say virologist in my profile... Anyway, as amends, please accept this cat. Bonus, one tired editor.

"This is the first public health emergency where EMA collaborates with the AMA since it has come into operation, alongside participating African NRAs." Regulatory requirements for approval key question. Do you need phase 3 human efficacy data? Will be hard...

this, and it’s important to understand the baseline here — this is still one of the largest outbreaks on record, and it’s going to get a lot larger before it can be brought under control.

PS I hope there won't be backlash for this dramatic reduction of suspected cases. This is not crying wolf. Ebola is a high consequence disease and you do not want to miss cases (and thus onward transmission). Initial PH and testing just wasn't there to properly classify all these suspected cases.

Some updates from this: -Suspected cases reduced from ~1k to 116 (due to follow up and rule out) -8 recovered -Also looking at suspected deaths (223 currently but might reduce once all of these have been investigated) -Testing capacity atm ~1k/d -45% of contacts traced

📣 Join our press conference, hosted by WHO Director-General Tedros Adhanom Ghebreyesus on #ebola Bundibugyo and other global health issues. 🗓️ Today at 15.00 CEST (GMT+2) Livestream via WHO's X, Facebook, LinkedIn & YouTube

“But while the need for better tests has been clear for years, there has been little investment to develop them because there is no high-income market, said Sonjelle Shilton, who works [] for the aid group Doctors Without Borders.” Great story on Ebola diagnostics in current outbreak 🧪 #giftlink

Puzzled, what is the point of sending an email to say you will submit an article? Why not just submit? Presub enquiries are fine, of course. But telling me you'll submit is not the same as asking me whether you should...

New research article Real-world emergence of #nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France www.thelancet.com/journals/lan... #IDSky #ClinMicro #RSV #AMR #OpenAccess #OA

Better diagnostics could have limited this Ebola outbreak www.nature.com/articles/d41...

"In this proof-of-concept study, 4 months of delamanid, bedaquiline, and quabodepistat showed a promising end-of-treatment non-inferiority signal versus 6 months of RHEZ and was generally well tolerated." @thelancetinfdis.bsky.social #IDSky #TBSky www.thelancet.com/journals/lan...

New letter by Uganda PH about the initial imported Bundibugyo cases in Kampala and their travel history. Check out the figure in appendix in particular.

infuriating

Bangladesh posts more than 1,300 measles cases, 2 deaths, in 1 day. The country’s tally now stands at nearly 71,000 infections and 585 fatalities since the crisis began in mid-March. Read more: ow.ly/ncJs50Z6lXF 📷: King County / Flickr cc

Among patients with #GramNegativeBacteremia, rapid #AntimicrobialSusceptibilityTesting did not improve 30-day clinical outcomes compared with standard testing, despite providing faster guidance for antibiotic escalation or deescalation. ja.ma/4efFl7l

ARTIC network has published Bundibugyo (BDBV) sequencing resources as the 2026 outbreak continues in DRC & Uganda. We have compiled guidance for labs wishing to sequence, assemble and analyse BDBV genomes: artic.network/viruses/bdbv/bdbv-sequencing-guide.html

Quick reminder, it's highly, highly likely that anyone travelling from DRC developing fever has some other infection than Ebola. Proper IPC and testing key.

New research article VRON-0200 alone and in combination with investigational antivirals for participants with chronic #hepatitis B virus infection receiving stable nucleos(t)ide therapy www.thelancet.com/journals/lan... #IDSky #ClinMicro #ViroSky #HBV #OpenAccess #OA

🎙️ Just published Communicable E54: ESCMID Global Late Breakers, part 2 Hosted by our editors - Erin McCreary, PharmD, Josh Davis, Marc Bonten, Anne-Grete Märtson, Angela Huttner 🌟 Listen on #Communicable: https://share.transistor.fm/s/a8cc04bb#Communicable #ESCMIDGlobal2026 #IDSky #clinmicro

New Research Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial www.thelancet.com/journals/lan...

DoxyPEP is not just a CDC recommendation anymore. WHO also endorses! www.who.int/news/item/28... #IDSky

📣 New publication: First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib: www.clinicalmicrobiologyandinfection.org/article/S119... #hantavirus

Read this to understand why the current Ebola outbreak in a conflict zone with scarce resources, is likely to end up as the largest and most deadly in history www.nytimes.com/2026/05/30/w...

New editorial Key facts about the Bundibugyo virus outbreak www.thelancet.com/journals/lan...

🧪 #Bundibugyo #EbolaDisease 🇨🇩 „African health workers have provided the bulk of the frontline care during a series of Ebola outbreaks“ HT @leoguari.bsky.social Explore this gift article from The New York Times. You can read it for free without a subscription. www.nytimes.com/2026/05/20/w...

New review article From microbiomes to predictive ecosystems: challenges and opportunities in artificial intelligence-based approaches www.thelancet.com/journals/lan... #IDSky #ClinMicro #microbiome #AI #OpenAccess #OA

Brazilian lemonade from the local coffee cart. Improves my meeting experience massively.

My much more radical opinion is that all ethical approvals for human/animal biomedical research should be openly published, and all papers resulting from those studies should be easily linked to the approval. This one *really* freaks people out and I suspect we all know why.

Rushing to publish something informative that is related to a major outbreak makes sense. But rushing to publish something just to capitalise on the topicality of said outbreak leaves a bad impression.

We’re hiring 2 Research Associates to work on health and climate change. The roles will contribute to the development and evaluation of indicators and wider research on mitigation and health, supporting mitigation‑focused research for Working Group 3. Deadline: 25/06/2026 Apply: buff.ly/xAUuJQC

US data show ‘alarming’ increase in multidrug-resistance gene. CDC scientists report the proportion of carbapenem-resistant Enterobacterales carrying the NDM gene rose from 5% in 2016 to 40% in 2023. Read more: ow.ly/1iM550Z5j4o 📷: Stephanie Rossow/CDC

New editorial for anyone who needs a quick primer on Bundibugyo virus 👇

New issue has dropped! Love the cover, inspired by an article on mpox in children in DRC.

My job is email 🙃 [I'm exaggerating; I love my job but the last couple days/weeks have been... a lot. So many unnecessary or actively stupid emails. Complaint over, onwards and upwards.]

"We are fighting for the same cause: to save human lives from this Ebola epidemic" This sentence struck me hard, because it's clear from the wider discourse that many need reminding of the humanity of those affected. www.theguardian.com/global-devel...

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. https://nej.md/4fKe9ib #EASL

Reposting for the morning crowd -- come work with us!

Oh no, AI companies are now even leaving voicemail for their newest publishing disruption grift and I don't even have a work phone number... Please make it stop.

The Trump administration has tightened communications by a key U.S. health agency. The National Institute of Allergy and Infectious Diseases is barred from directly engaging with the World Health Organization. www.healthday.com/health-news/...

Spotted: Hugo on emergency callout

🚨🦠🦟🧬👩‍🔬 We are looking for a Senior Editor to cover parental leave, starting ~Sept. This is your chance to come work for The Lancet Infectious Diseases! Awesome team, best speciality, lots of flexibility. Previous editorial experience not required; need to be ID nerd 🤓 Apply below or get in touch 👇

New correspondence by Velavan, Kremsner and Ntoumi "The current PHEIC highlights the risk of preparedness that repeatedly prioritises one virus species"

I’ll be at #EASLCongress in Barcelona for @lancetgastrohep.bsky.social this week — drop me a line if you’d like to catch up! #LiverSky #MedSky #EASL2026

One glimmer of hope in the Ebola response: Within hours of the outbreak in DRC being declared, researchers convened to prepare drug trials. A lot has changed on that front since the Ebola outbreak in West Africa a decade ago. But huge challenges remain 🧪 My story in @science.org (🧵 to come)